Verovaccines
Biopharmaceutical company developing an adaptable vaccine platform for animal health based on recombinant yeast expression. The platform uses engineered eukaryotic yeast strains to express antigens (including formation of virus-like particles), supports multivalent vaccine design, and has been validated across multiple animal vaccine programs. The company reports capabilities in fermentation/bioprocess development, scale-up to GMP manufacturing with partners, preclinical/target-animal efficacy studies, and regulatory submissions to European authorities.
Industries
Nr. of Employees
small (1-50)
Verovaccines
Patents
Optimized host/vector system for producing protective mono-and multivalent subunit vaccines on the basis of the yeast Kluyveromyces lactis
US-12473562-B2
View DetailsOptimized host/vector system for producing protective mono- and multivalent subunit vaccines on the basis of the yeast Kluyveromyces lactis
US-11905517-B2
View DetailsVaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens
US-11065312-B2
View Details
Optimized host/vector system for producing protective mono-and multivalent subunit vaccines on the basis of the yeast Kluyveromyces lactis
US-12473562-B2
View DetailsOptimized host/vector system for producing protective mono- and multivalent subunit vaccines on the basis of the yeast Kluyveromyces lactis
US-11905517-B2
View DetailsVaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens
US-11065312-B2
View DetailsProducts
Recombinant yeast-based veterinary vaccines (pipeline)
A pipeline of subunit vaccines derived from recombinant yeast expression targeting rapidly mutating animal pathogens (examples include bluetongue virus type 3 and other livestock pathogens).
Recombinant yeast-based veterinary vaccines (pipeline)
A pipeline of subunit vaccines derived from recombinant yeast expression targeting rapidly mutating animal pathogens (examples include bluetongue virus type 3 and other livestock pathogens).
Services
Collaborative programs and licensing/out-licensing of the recombinant yeast-based vaccine platform to develop veterinary vaccines in partnership with pharmaceutical companies.
Collaborative programs and licensing/out-licensing of the recombinant yeast-based vaccine platform to develop veterinary vaccines in partnership with pharmaceutical companies.
Expertise Areas
- Animal vaccine development
- Vaccine platform engineering
- Fermentation and bioprocess development
- Scale-up and GMP manufacturing
Key Technologies
- Recombinant yeast expression
- Virus-like particle (VLP) production
- Subunit vaccine design
- Multivalent antigen assembly
News & Updates
Participation and presentations on vaccine R&D and platform innovation.
Presentation of the Unified Vaccine Platform and technology updates.
Marketing authorization granted for a recombinant BTV vaccine (EU-wide).
Recommendation from European Medicines Agency (CVMP) for approval of a first member of a new vaccine class.
Establishment of full-scale production under GMP with a manufacturing partner.
Awarded a 3.1 million euro research grant from the GO-Bio funding program for animal vaccine development.
Participation and presentations on vaccine R&D and platform innovation.
Presentation of the Unified Vaccine Platform and technology updates.
Marketing authorization granted for a recombinant BTV vaccine (EU-wide).
Recommendation from European Medicines Agency (CVMP) for approval of a first member of a new vaccine class.
Establishment of full-scale production under GMP with a manufacturing partner.
Awarded a 3.1 million euro research grant from the GO-Bio funding program for animal vaccine development.